Antihepcidin Antibody Treatment Modulates Iron Metabolism and Is Effective in a Mouse Model of Inflammation-Induced Anemia

The study investigated the effects of antihepcidin antibody treatment on iron metabolism in a mouse model of inflammation-induced anemia. It demonstrated that targeting hepcidin, a key regulator of iron homeostasis, could alleviate anemia symptoms by improving iron availability for erythropoiesis. Overexpression of hepcidin in mice led to iron deficiency, stunted growth, and hair loss, while antibody treatment neutralized hepcidin, improved iron transport, and treated anemia. The combination of hepcidin suppression and erythropoiesis-stimulating agent (ESA) treatment showed a synergistic effect, suggesting potential therapeutic benefits for conditions associated with anemia of inflammation. The study provided a basis for further exploration of antihepcidin therapies in clinical settings.